Cytosorbents EBITDA 2010-2025 | CTSO

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Cytosorbents ebitda from 2010 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Cytosorbents ebitda from 2010 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Related Stocks
Company Name	Market Cap
Abbott Laboratories (ABT)	$228B
Boston Scientific (BSX)	$152.1B
Stryker (SYK)	$144B
EssilorLuxottica (ESLOY)	$137.5B
Medtronic (MDT)	$118B
Lonza Group Ag (LZAGY)	$47.5B
Haleon (HLN)	$43B
ResMed (RMD)	$41.5B
GE HealthCare Technologies (GEHC)	$34B
Agilent Technologies (A)	$33.3B
Terumo (TRUMY)	$27.6B
Koninklijke Philips (PHG)	$26B
Insulet (PODD)	$21.8B
Zimmer Biomet Holdings (ZBH)	$20.2B
Smith & Nephew SNATS (SNN)	$15.9B
Baxter (BAX)	$12.3B
Sunny Optical Technology (SNPTF)	$10.8B
Demant (WILYY)	$8.2B
Bio-Rad Laboratories (BIO)	$7.4B
Lantheus Holdings (LNTH)	$3.7B
Envista Holdings (NVST)	$3.5B
Shandong Weigao Medical Polymer (SHWGF)	$3.5B
Prestige Consumer Healthcare (PBH)	$3.2B
Perrigo (PRGO)	$3.2B
ICU Medical (ICUI)	$2.7B
Haemonetics (HAE)	$2.5B
LeMaitre Vascular (LMAT)	$2.1B
Curaleaf Holdings (CURLF)	$1.8B
AtriCure (ATRC)	$1.8B
Green Thumb Industries (GTBIF)	$1.7B